Product Code: | RE-CV2-NCR-4 | |
Protein: | SARS-CoV-2 Nucleocapsid, RNA binding domain (aa 46- aa 173) | |
Volume: | 1mg | |
Source: | E. coli | |
Mol. Wt: | 15 kD | |
Purification: | Purified from E. coli by multi-step chromatography. | |
Purity: | Purity >95% by silver stain SDS-PAGE and InBio®MS (LC-MS/MS, relative abundance). | |
Validation: | Validated by IgG antibody ELISA using serum samples (n=10) from COVID-19 patients. | |
Concentration: | xx based on OD 280nm. Extinction Coefficient = 1.8. | |
Formulation: | Preservative and carrier-free in 0.3M NaCl, 1X PBS, pH 7.4. Filtered through 0.22µm filter. | |
Storage: | Store at -20ºC. Avoid repeated freeze-thaw cycles. | |
Notes: | (1) SARS-CoV-2 NCR has a C-terminal 7xHis-tag. (2) Point mutation (P46G) introduced to increase stability. | |
An InBio® product. Made in the USA | ||
Indoor Biotechnologies 由三家附属公司组成,INDOOR Biotechnologies Inc.(IBI),位于美国弗吉尼亚州夏洛茨维尔,INDOOR Biotechnologies Limited(IBL)位于英国卡迪夫,INDOOR Biotechnologies India(IBIndia),新设立于班加罗尔。Indoor Biotechnologies 遍布全球,在日本,中国和韩国拥有授权分销商,在全球约50个国家/地区销售。 Indoor Biotechnologies 生产纯化的天然和重组过敏原,用于研究和开发过敏诊断和疫苗。该产品系列目前包括 50 种纯化的过敏原,其制造具有高纯度和生物活性。这包括具有低内毒素含量的 LoTox™ 过敏原,专为过敏和哮喘的免疫学研究而设计。